Effective application of Risk Management techniques to Drug Safety: a pragmatic approach
|
|
- Eugene Rose
- 5 years ago
- Views:
Transcription
1 Effective application of Risk Management techniques to Drug Safety: a pragmatic approach Dr Mark Perrott WCI Consulting ltd 19th October Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners. 2
2 I have worked with pvnet to develop this view of Risk Management in Drug Safety I have worked with the pvnet group of companies to look at the current state of Safety Risk Management (SRM) across industry and to identify key considerations in implementing these approaches pvnet was founded in 2001 In 2009 its membership comprises ~15 of the top 20 pharmaceutical companies with objectives to: Describe & compare performance of global drug safety operations Share best practices, debate common challenges and challenge the status quo Provide a focus for developing future solutions for effective drug safety 3 Risk Management has been a formal process in a number of industries for many years Risk Management is commonly used across aerospace, nuclear and financial (e.g. insurance) industries to identify, prioritize and manage risks Several widely-used models have been developed of which one of the most well known is the Failure Mode Effects and Criticality Analysis (FMECA) Internal and external drivers have recently resulted in the adoption of Risk Management practices in drug safety 4
3 Drug Safety teams need to ensure patient safety in a rapidly changing environment Evolving regulations and initiatives (e.g., Volume 9A, Report of the EU Commission on PV, IOM Report on the US Drug Safety System, FDAAA, Sentinel initiative) Safety risk management from development to end of lifecycle Proactive Data mining, Signal detection and management + response to authority signals from external databases Post authorization safety studies QPPV oversight of safety and risk management systems 5 Regulatory authorities have formalised requirements for Safety Risk Management EU Vol 9a: The EMEA has clear expectations for European Risk Management Plans (EU-RMPs) which must be provided as a core element of almost all submissions in the EU. US FDA AA: A Risk Evaluation and Mitigation Strategy (REMS) will be required if the FDA finds that one is necessary to ensure that the benefits of the drug or biological product outweigh the risks of the product. The FDA currently may require a REMS, and has required them only for a small number of pharmaceutical products. In each case, where an RMP or REMS is required, the risk management actions are considered to be commitments upon which any product approval is conditional In addition, both the EMEA and FDA have formal powers of enforcement from significant fines through to product license withdrawal for non-compliance 6
4 Key questions that Pharma companies must successfully address How can Pharma companies ensure that they identify and manage safety risks during a product s life to ensure effective Safety Risk Management How should Safety Risk Management be incorporated into business models to meet current and future expectations? What approaches are proving to be the most effective way to deliver effective Safety Risk Management? What does this change in the relationships with interfacing functions? What are the key considerations in implementing safety Risk Management Plans in the real world? 7 This Good Risk Management Practice model meets pharmaceutical industry needs 0. Establish the governance and team structures 1. Identify risks from all relevant sources 2. Characterise safety risks 3. Assess the severity and likelihood of safety risks, develop mitigation actions 4. Manage the implementation of mitigation actions 5. Monitor the effectiveness of the mitigation actions 8
5 There are 5 key principles to effective lifecycle Safety Risk Management 1. Build and support a proactive safety culture in development by including Safety Risk Management milestones in the Development process 2. Implement the CIOMS VI Safety Management Team concept into current project management approaches 3. Integrate Safety Risk Management with key Safety processes (e.g. lifecycle signal detection and management) 4. Build clarity into the accountabilities and relationships of the SMT with other teams and functions 5. Ensure SRM actions and commitments are carried out and effective 9 1.Build a proactive safety culture by including Safety Risk Management milestones in the Development process Pre-Phase I Phase I Phase II Phase III: Submit / Launch Lifecycle Management First safety spec. First development RMP Submission RMP Update and expand Manage implementation Develop go / no-go safety criteria and documentation expectations for each development decision point Build safety knowledge from pre-clinical through to market to enable continuity of safety risk management Ensure that all necessary skills and knowledge are brought together at key points 10
6 2. Implement the CIOMS VI Safety Management Team concept into project management approaches Pre-Phase I Phase I Phase II Phase III: Submit / Launch Lifecycle Management Safety input to Project decision points comes from the right skills at the right time SMT Pre-Clinical & Clinical The bar thickness is an example only of the relative contribution of functions, this will vary by SMT PV (lead) Medical Affairs SMT: Holistic view of product safety risk comes from the contribution of pre-clinical, clinical, epidemiology and others, led by safety One SMT per Clinical Development project and per enhanced PV - marketed product Functional input to key safety decisions depends on lifecycle phase Integrate Safety Risk Management with key Safety processes Start with aligned safety event management across Clinical and Safety Agreed safety-based study entry and stopping criteria SAE processing Routine safety reviews (e.g. SMT, toxicity boards) Sentinel events Integration with signal detection governance across the lifecycle, don t just focus on post-marketing New skills required: Safety managers must become leaders in the SMT A combination of clinical statistical interpretation (aggregate data) and pharmacovigilance analysis (case, or detail-oriented) 12
7 4. Build clarity into the accountabilities and relationships of the SMT with other teams A formalised safety culture in Development is a new concept for many companies Roles and responsibilities for safety monitoring and governance must be established in particular for the independent role of Safety, with clear accountability for benefit : risk established across the teams Establish the relationship between Clinical and Safety roles as peer to peer, with equal weight and access to independent escalation Clear and simple governance for risk, enabling rapid escalation of issues to senior decision-makers Ensure Safety Risk Management actions are carried out and effective Many post-approval safety risk management commitments will require the full co-operation of commercial functions or external partners Ensure all stakeholders clearly understand the nature of the risks, commitments made and consequences of failure May need very senior management endorsement to assure compliance Jointly define measures of implementation and effectiveness (with safety oversight) Clarify roles and responsibilities for each type of risk management action to ensure clarity across the organisation Maintain accountability in Safety for monitoring effectiveness to provide single point control, clear governance and the opportunity for intervention 14
8 It is critical that all steps are included and the loop is closed Having identified, characterised and prioritised safety risks: The actions required to manage risk may be difficult to define, design and implement completely as they are often owned by commercial functions Governance of R&D and commercial typically do not meet until board level When implementing safety risk management, it is imperative to put the mechanisms in place to manage the required actions before establishing where the greatest risks exist in the business 15 Effective Development Safety Risk Management brings internal benefits Establishes stronger safety culture within the organization Earlier Safety involvement in development can lead to earlier discontinuation of unsuccessful projects; lower costs, company protection Early, high quality, risk mitigation Strengthened life cycle Safety Surveillance approach Safety involvement facilitates sharing lessons learned across projects 16
9 which may have valuable commercial implications Pharma company focus Sales: Lost sales due to suboptimal pharmacovigilance Future? Traditionally Pharma already spends millions of dollars protecting patents Max sales potential $m Sales Revenue: Strategies to hasten speed to market can increase sales potential and longevity Sales impacted by poor pharmacovigilance Cost Time Costs: Front loading pharmacovigilance can minimize total cost, and reduce risk of exposure to future costs Source: Datamonitor Healthcare March , London, UK 17 and which impact positively on the external facing safety profile of a company. Better, earlier characterization of the benefit / risk profile Better Risk Management Plans No surprises pre-approval / post-marketing Getting answers earlier leads to better risk management And may reduce commitments required post-approval Good labelling, reduced downstream changes Gain Regulatory confidence 18
10 Contact information Dr. Mark Perrott Managing Consultant Tel: +44 (0)
QPPV Association and Training Part 2 Session Introduction
QPPV Association and Training Part 2 Session Introduction Steve Douglas QPPV SGD Consulting Limited PrimeVigilance Ltd Disclaimer The views and opinions expressed in the following PowerPoint slides are
More informationLabelling Harmonization 2011
Labelling Harmonization 2011 DIA, Bethesda, MD Core Labeling During Clinical Development Su Yueh Lin Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual
More informationPharmacovigilance in Asia: The China Perspectives. Disclaimer
Pharmacovigilance in Asia: The China Perspectives Rebecca Wang, MD, FRCP, FACC Head, Product Development Drug Safety Operation, Asia Pacific Roche Shanghai Disclaimer The views and opinions expressed in
More informationPharmacovigilance Post July 2012 The new frontier
Pharmacovigilance Post July 2012 The new frontier Colleen Walsh Head, Safety and Benefit Risk Management Quality, Biogen Idec 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The
More informationFDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives
Session Overview (1) Although the role of the Qualified Person responsible for Pharmacovigilance is mandated by the European legislation, the QPPV is held responsible for the establishment and the maintenance
More informationDelivering GxP compliant mobile applications a practical case study. Presented by: Mark Stevens
Delivering GxP compliant mobile applications a practical case study Presented by: Mark Stevens Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual
More informationDo Niche CROs have a Role in Drug Development?
Do Niche CROs have a Role in Drug Development? Dr Nermeen Varawalla, MD, DPhil (Oxon), MBA President & CEO ECCRO 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationProject Management Standards Applied to Complex Clinical Trials. Disclaimer
Project Management Standards Applied to Complex Clinical Trials Alexander Gissler, PMP ProjectPharm Ltd., Owner & Director 1 Disclaimer The views and opinions expressed in the following PowerPoint slides
More informationConstructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer
Constructing an etmf The do s and don ts of EDM Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug
More informationPromotional Materials. System Approach. Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company
Promotional Materials and a Quality Management System Approach Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company Disclaimer The views and opinions expressed in the
More informationWhat is an ideal PSUR? A new focus based on aligned expectations
What is an ideal PSUR? A new focus based on aligned expectations Margarida Guimarães PRAC Member INFARMED, I.P. Periodic Safety Update Report Information Day 28 October 2016 London, UK Disclaimer The views
More informationSystematic Risk Management: An Overview of ICH Q-9
Systematic Risk Management: An Overview of ICH Q-9 March 12, 2014 12014 ParagonRx International LLC Today s Session Systematic Risk Management: An Overview of ICH Q-9 Speakers: Jeff Fetterman, President,
More informationAndrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here. Disclaimer
Fit for the future - A new strategic approach to Medical Information management within GSK Andrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here 1 Disclaimer The
More informationHow to successfully Implement and Leverage the Regulatory Intelligence Function
How to successfully Implement and Leverage the Regulatory Intelligence Function Marianne Koehne EU RI Network Group; Global RI Manager Boehringer Ingelheim 26th Annual EuroMeeting 25-27 March 2014 ACV,
More informationEnsuring patient safety and regulatory compliance in an era of ever expanding complexity: Key considerations for today s pharmacovigilance leader
FOR PHARMA & LIFE SCIENCES WHITE PAPER Ensuring patient safety and regulatory compliance in an era of ever expanding complexity: Key considerations for today s pharmacovigilance leader SUMMARY There is
More informationA practical guide to achieving and maintaining global oversight and ensuring end-to-end pharmacovigilance
FOR PHARMA & LIFE SCIENCES WHITE PAPER A practical guide to achieving and maintaining global oversight and ensuring end-to-end pharmacovigilance The increasing complexity of today s pharmaceutical industry
More informationThe Case for Streamlined Complaints Management in Medical Devices. Consulting
The Case for Streamlined Complaints Management in Medical Devices Consulting Increasing challenges in the evolving medical industry will require a more integrated complaints management approach The medical
More informationHow can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise
How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise 10 th Latin American Conference on Clinical Research, October 2013 Xavier Luria, MD Drug Development and Regulation
More informationThe Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports
The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports Dr Brian Edwards Scientific Adviser, Pharmacovigilance & Drug Safety, NDA Regulatory Science Ltd DIA 3rd
More informationIncorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance
Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria. Disclaimer The
More informationNew Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)
New Regulation in Japan and Future Direction of PMDA Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org June 19, 2008 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationMaintenance of Mature and Generic Products
Maintenance of Mature and Generic Products A Pragmatic Approach to Successfully Navigating the Safety and Regulatory Continuum Background While development of promising new products is an obvious area
More informationStepping Into the Future of Pharmacovigilance
PAREXEL White Paper Stepping Into the Future of Pharmacovigilance The What, Why and How of Knowledge Process Outsourcing Mature biopharmaceutical products with established safety profiles frequently represent
More informationSPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs
SPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs Doris Sincak Project Supervisor Sanofi Disclaimers DIA The views and opinions expressed in the following PowerPoint slides
More informationAdvance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?
Advance Topics in Pharmacoepidemiology Risk Management 2012 Mid-Year ISPE Meeting Miami, April 21-23, 2012 Ariel E., Arias MD, PhD - Fac. Pharmacy; Université de Montréal - Biologics & Genetic Therapies
More informationAgency and Internal Labeling
Agency and Internal Labeling Audits Joseph McMillian, MA Heartland Compliance Services LLC Internal Labeling Audits The views and opinions expressed in the following PowerPoint slides are those of the
More informationUpdate on New MedDRA SOC Product issues
Update on New MedDRA SOC Product issues Judy Harrison, M.D. Chief Medical Officer, MedDRA MSSO ICSR Information Day 26 April 2016 London, UK Disclaimer The views and opinions expressed in the following
More informationHigh Quality or Poor Quality DB
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,
More informationLabelling & Naming. European Biosimilars Group (EBG) perspective. >400 Million patient days worldwide clinical experience with EU biosimilar medicines
Labelling & Naming European Biosimilars Group (EBG) perspective >400 Million patient days worldwide clinical experience with EU biosimilar medicines Elke Grooten, Director Public Affairs Sandoz Europe
More informationEffective Project Leadership and Management: Disclaimer
Effective Project Leadership and Management: A CRO Perspective Nita Ichhpurani, B.S., PMP Director, Drug Development Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationQbD approach and Regulatory Challenges in Europe
QbD approach and Regulatory Challenges in Europe DIA 26th Annual EuroMeeting, Vienna 2014 Dr Peter Richardson Head of Quality, European Medicines Agency An agency of the European Union Disclaimer The views
More informationPharmacovigilance - Regulatory perspective -
Pharmacovigilance - Regulatory perspective - Junko Sato Director for Risk Management, Office of Safety Pharmaceuticals and Medical Devices Agency (PMDA) Agenda Concept of Phamacovigilance Current Regulation
More informationSafety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington
Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington DISCLAIMER These materials have been prepared solely for educational
More informationSharing Regulatory Intelligence: Best Practices and Case Studies
Sharing Regulatory Intelligence: Best Practices and Case Studies Carolyn Hynes Sr. Director, Global Regulatory Intelligence, GlaxoSmithKline 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria
More informationPanama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA)
DIA Latin American Regulatory Conference Panama City, Panama April, 12-15, 2011 Biosimilars/Biotechnology Marcelo Mario Matos Moreira Coordinator Office of Biological Products The Brazilian Health Surveillance
More informationRegulatory Aspects of Pharmacovigilance
Regulatory Aspects of Pharmacovigilance Deirdre Mc Carthy Pia Caduff-Janosa Training Course Uppsala 2012 Agenda Risk based approach to spontaneous reporting (incl clinical trials) -> Pia Caduff-Janosa
More informationPMDA Town Hall. Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)
PMDA Town Hall - New Regulation in Japan and Future Direction of PMDA Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed
More informationAn integrated model approach to improve the management of marketed products
Insight brief Regulatory and safety integration An integrated model approach to improve the management of marketed products Leo Dodds, Principal, Quintiles Advisory Services John Rogers, Engagement Leader,
More informationName of employee: Revised: Title: Department name: (e.g. Patient Solutions Thrombosis) Org. Unit ID (optional): (e.g ) Location: Job type:
1. JOB DESCRIPTION Please fill in this form and save it as described in SOP_000151. Background information Name of employee: (John Doe) LEO-id: (AAAUS) Revised: (date and version) Title: (E.g. Specialist,
More informationUpdate on Real World Evidence Data Collection
Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large
More information395 South Youngs Road Buffalo, New York cognigencorp.com An On-Site 2-Day Workshop in Engineering The Pharmacometric Enterprise
395 South Youngs Road Buffalo, New York 14221 716.633.3463 cognigencorp.com An On-Site 2-Day Workshop in Engineering The Pharmacometric Enterprise A Workshop For Improving the Efficiency and Effectiveness
More informationImplementing Benefit-Risk Management More Effectively
Implementing Benefit-Risk Management More Effectively Steve Mayall, Principal Consultant June 2017 Pope Woodhead & Associates Ltd. The Old Grammar School, 1 Ramsey Road, St. Ives, Cambridgeshire, PE27
More informationHOT TOPICS IN PV. Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva
HOT TOPICS IN PV International Society of Pharmacovigilance Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva Dr Irene FERMONT, MD, MSc, EUQPPV ISOP ISRAEL Coordinator
More informationICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon
ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author
More informationPMDA Update. - New Regulation in Japan and Future Direction of PMDA
PMDA Update - New Regulation in Japan and Future Direction of PMDA Kazuhiro SHIGETO, M.D., M.P.H., Ph.D. Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and
More informationThe Future of Pharmacovigilance
The Future of Pharmacovigilance Leveraging Technology to Transform the Safety Continuum Background The pharmaceutical industry is set to embrace transformation initiatives at a faster pace over the coming
More informationPractising Safety THE ROLE OF PHARMACOVIGILANCE IN PHARMACOECONOMICS
Practising Safety THE ROLE OF PHARMACOVIGILANCE IN PHARMACOECONOMICS Coimbatore, India London, United Kingdom Disclaimer The views and opinions expressed in this presentation do not necessarily reflect
More informationUsing etechnologies to Increase Efficiency and Quality in Regulatory Operations
Using etechnologies to Increase Efficiency and Quality in Regulatory Operations Tim Powell Submissions Management Global Regulatory Affairs Disclaimer The views and opinions expressed in the following
More informationMANAGING MATURE PRODUCT PORTFOLIOS - KEY CHALLENGES AND BENEFITS
WHITEPAPER MANAGING MATURE PRODUCT PORTFOLIOS - KEY CHALLENGES AND BENEFITS Dr. Constanze Burkhardt Senior Director, Strategic Outsourcing constanze.burkhardt@pharmalex.com Constanze has worked for PharmaLex
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationHands-on in Latin America Regulations for Clinical Trials
Hands-on in Latin America Regulations for Clinical Trials Director: Silvia Zieher VP Clinical Development, Latin America Operations INC Research Disclaimer The views and opinions expressed in the following
More informationStakeholder education on biosimilar concepts - why does it matter globally?
Stakeholder education on biosimilar concepts - why does it matter globally? Dr Virginia Acha Director, Regulatory Policy Europe, Middle East and Africa Amgen 26th Annual EuroMeeting 25-27 March 2014 ACV,
More informationJob Title: Head, Clinical Science Job Location: Nanjing, China CV to: Wechat:
Job Title: Head, Clinical Science Job Description: As a senior member of the Clinical Development organization, the Head of Clinical Science will supervise a team of staff to lead the clinical development
More informationActive Essex Risk Management Strategy
Active Essex Risk Management Strategy 2017-2021 November 2017 Contents 1. Policy Statement 2. Statement of Commitment 3. Risk Management Framework 4. Risk Appetite 5. Risk Maturity 6. Risk Management Levels
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationStructured Content Management [SCM]
Structured Content Management [SCM] Lessons learned from SCM implementations Shailesh Shah ArborSys Group Ole Rom Andersen CEO, DITA Exchange Inc. The views and opinions expressed in the following PowerPoint
More informationProduct Stewardship: Impact on Brand, Compliance, and Risk Management
Product Stewardship: Impact on Brand, Compliance, and Risk Management John Phillips Technical Director Product Stewardship, North America December 2016 www.erm.com The business of sustainability Product
More informationGeorge Bernstein, Ph.D. Double Dragon Consulting
George Bernstein, Ph.D. Double Dragon Consulting 9/30/2008 Copyright 2016 George Bernstein The Problem The Solution Quality Standards vs. SOPs Example Quality Standards Clinical Development Pharmacovigilance
More informationProject Management Competencies. Disclaimer 28/06/2011
Project Management Competencies Martin D. Hynes III, Ph.D. Senior Director Product Research & Development Lilly Research Laboratories Eli Lilly and Company Indianapolis, IN Disclaimer The views and opinions
More informationCurrent Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals
15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight V5-S3 Current
More informationEugène van Puijenbroek, MD, PhD
Signal detection and signal management at the Netherlands Pharmacovigilance il Centre EudraVigilance Information Day 1 July 2009 Eugène van Puijenbroek, MD, PhD Disclaimer The views and opinions expressed
More informationInterdisciplinary Perspectives on Development of Naming Standards for Biosimilar Medicines
Interdisciplinary Perspectives on Development of Naming Standards for Biosimilar Medicines Richard Dolinar, MD Chairman, Alliance for Safe Biologic Medicines Disclaimer The views and opinions expressed
More informationCSR STRATEGY, GOVERNANCE & MATERIALITY
Stakeholder Importance (External) CSR STRATEGY, GOVERNANCE & MATERIALITY G4 indicators: G4-18, G4-19, G4-20, G4-21, G4-24, G4-27, G4-56 CSR STRATEGY Our Corporate Social Responsibility (CSR) strategy is
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationLegislative and Regulatory Modernization for Therapeutic Products
Legislative and Regulatory Modernization for Therapeutic Products Maurica Maher Associate Director, Office of Legislative and Regulatory Modernization, Health Products and Food Branch, Health Canada Presented
More informationThe Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach
The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach CADTH Symposium April 6, 2009 Maurica Maher, MD, MSc Associate Director Office of Legislative
More informationRegulatory Considerations and Evolving Issues Concerning REMS Programs
Regulatory Considerations and Evolving Issues Concerning REMS Programs Kathleen M. Sanzo ksanzo@morganlewis.com 202-739 739-5209 August 2009 1 Evolution of Risk Management AT FDA 1976 Patient package inserts
More informationGlobal Regulatory Director, Personalized Healthcare
Date: 11/21/18 Global Regulatory Director, Personalized Healthcare Job ID: 201811-127364 Job Function Research Location United States of America - California South San Francisco Schedule Full time Job
More informationPharmacovigilance System Master file
IMPLEMENTING MEASURES IN ORDER TO HARMONISE THE PERFORMANCE OF THE PHARMACOVIGILANCE ACTIVITIES PROVIDED FOR IN DIRECTIVE 2001/83/EC AND REGULATION (EC) NO 726/2004 Pharmacovigilance System Master file
More information8 th Kitasato- Harvard Symposium
8 th Kitasato- Harvard Symposium CONSISTENT SAFETY RISK MANAGEMENT THROUGH THE PRODUCUT LIFE CYCLE FROM CLINICAL DEVELOPEMNT TO POST APPROVAL - Efforts of Regulatory Authority in Japan - Kaoru Misawa Director,
More informationMedical Information Role in the Pharmaceutical Industry
www.arisglobal.com A White Paper Presented By ArisGlobal Medical Information Role in the Pharmaceutical Industry by Ome Ogbru, PharmD, SME, Medical Communications & Sanjay Kumar D, Product Marketing Manager
More informationIssues driving the EU Regulatory Agenda on Benefit-Risk Management: the Importance of Risk Minimisation Activities.
Issues driving the EU Regulatory Agenda on Benefit-Risk Management: the Importance of Risk Minimisation Activities. ISPE Mid Year Meeting 2011, Florence, Italy Almath Spooner Irish Medicines Board Disclaimer
More informationInto the Clouds. Understanding How Cloud Computing Will Effect the Future of Regulated Content Management. Jennifer Goldsmith
Into the Clouds Understanding How Cloud Computing Will Effect the Future of Regulated Content Management Jennifer Goldsmith Vice President, Veeva Vault Veeva Systems The views and opinions expressed in
More informationReducing the Risk of Noncompliance in Healthcare
Reducing the Risk of Noncompliance in Healthcare Oversights are costly, so it pays to simplify. By Maria Gordian and Jason Evers Maria Gordian is a partner with Bain & Company based in New York. Jason
More informationKorean and APEC Perspectives: Recent trends in the regulation of biotherapeutics
Korean and APEC Perspectives: Recent trends in the regulation of biotherapeutics Jeewon Joung Ministry of Food and Drug Safety Republic of Korea Outline I. Korean Regulatory updates for Biotherapeutics
More informationUser Interface Considerations for Drug-Device Combination Products Submitted in an ANDA
User Interface Considerations for Drug-Device Combination Products Submitted in an ANDA Irene Z. Chan, PharmD, BCPS Deputy Director, Division of Medication Error Prevention and Analysis Disclaimer For
More informationQ10 PHARMACEUTICAL QUALITY SYSTEM
Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights
More informationQuality Management in PV. Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017
Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017 - Pharmacovigilance System - Overall Quality objectives in PV - Quality Management System overview - Quality Management System requirements - Quality
More informationIs this a project? Do I really have to plan?
Project Weavers Successful Projects Don't Happen by Chance. 53 rd Annual WSHMMA Conference Matthew J. Weaver, PMP, CSM, ITIL President/CEO Project Weavers, LLC April 12, 2017 The content of this presentation
More informationelevating the role of finance at Mary Lanning Healthcare
CASE STUDY REPRINT November 2013 Amanda Hoffman Jay Spence healthcare financial management association hfma.org elevating the role of finance at Mary Lanning Healthcare One central Nebraska hospital sought
More informationHong Kong Launches New Rules on Biotech Listings
Hong Kong Launches New Rules on Biotech Listings May 2018 The Stock Exchange of Hong Kong Limited (the Exchange) has concluded its consultation on a listing regime for emerging and innovative companies
More informationQbD Approach and Regulatory Challenges in Japan
QbD Approach and Regulatory Challenges in Japan YOSHIHIRO MATSUDA Ph.D. Deputy Division Director Pharmaceuticals and Medical Devices Agency (PMDA) 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria
More informationWe appreciate the opportunity to submit these comments for your consideration.
February 28, 2018 European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom via email to rp-stats-qa@ema.europa.eu Dear Sir or Madam: The International Society for Pharmaceutical
More informationCompliance & Validation Validation of Software-as-a-Service (SaaS Solutions)
www.arisglobal.com A White Paper Presented By ArisGlobal Compliance & Validation Validation of Software-as-a-Service (SaaS Solutions) ARIS GLOBAL CORPORATE HEADQUARTERS ArisGlobal, 1266 East Main Street,
More informationCapabilities and Competencies in the New Medical Affairs: A Roadmap To Success. Charlotte Kremer Charlotte Raabe - Hielscher Mary Alice Dwyer
Capabilities and Competencies in the New Medical Affairs: A Roadmap To Success Charlotte Kremer Charlotte Raabe - Hielscher Mary Alice Dwyer 1 External Trends in Healthcare: Are We Ready? 1. Increasing
More informationThe views and opinions expressed in the following PowerPoint slides are
Expedited Reporting of Important Changes to Foreign Safety Labeling and Expected Collaboration among Companies in Japan Rie Matsui, RPh Senior Manager, Post Marketing Regulatory Strategy, Pfizer Japan
More informationMethods to Demonstrate a Financial Return on Investment in Product Stewardship
Methods to Demonstrate a Financial Return on Investment in Product Stewardship John Phillips Technical Director Product Stewardship, North America December 2016 www.erm.com The business of sustainability
More informationAdverse Event Reporting
Adverse Event Reporting AE Case Receipt When we receive a case, we induct it through a well-oiled process that reduces the number of subsequent queries, classifies events appropriately, and increases the
More informationMircea Ciuca, MD Global Head Medical & Clinical Drug Safety
Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor,
More informationMARKET ACCESS & PUBLIC AFFAIRS MANAGER BELUX
MARKET ACCESS & PUBLIC AFFAIRS MANAGER BELUX Sofie Paeps Valerie Van Sannen Senior Executive Search Consultant Executive Search Consultant 0032.478.93.15.11 0032.485.97.52.32 sofie.paeps@hronegroup.com
More informationHEALTH PURCHASING VICTORIA STRATEGY. December 2017
HEALTH PURCHASING VICTORIA 2018-2022 STRATEGY December 2017 CONTENTS Contents... 2 Executive Summary... 3 Operating Environment... 5 HPV Vision and Values... 9 HPV Strategy 2018-2022: Framework... 10 HPV
More informationDrug Safety at Health Canada Presentation to CADTH
Drug Safety at Health Canada Presentation to CADTH Kimby N. Barton Director, Bureau of Cardiology, Allergy and Neurological Sciences and Chair, Health Portfolio Risk Management Planning WG April 16, 2012
More informationNew pharmacovigilance systems and services
New pharmacovigilance systems and services 17 September 2015, PCWP/HCPWP joint meeting Presented by Peter Arlett, Head of Pharmacovigilance department An agency of the European Union Background The new
More informationII.B.4. Information to be contained in the PSMF/ PSSF
II.B.4. Information to be contained in the PSMF/ PSSF No. PSMF/ PSSF section Remarks Cover Page: 1- The unique number (Revision No.) 2- The name of the MAH, QPPV or LSR (including third party). 3- The
More informationectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA
ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationPHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008
PHARMA CONGRESS October 28, 2008 Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments Beverly H. Lorell, MD Senior Medical & Policy Advisor King & Spalding LLP Assessing
More informationTextvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf
Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern
More informationfocus Pharmacovigilance Focus
focus 2 Pharmacovigilance Is there a difference in perceived practices between innovative and generic industries? Part 1: Analysis of spontaneous reporting practices in innovative and generic companies
More informationI modelli di governance dei processi nelle multinazionali
I modelli di governance dei processi nelle multinazionali Federico Pantellini, MD Medical Affairs Director Hematology-Oncology Celgene srl Roma 26/01/2017 Summary Putting process governance in the context:
More information